288 related articles for article (PubMed ID: 7970492)
21. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
22. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Paulick R; Caffier H; Paulick M
Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
[TBL] [Abstract][Full Text] [Related]
23. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
[TBL] [Abstract][Full Text] [Related]
24. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
[TBL] [Abstract][Full Text] [Related]
25. Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
Lee YC; Yang PC; Kuo SH; Luh KT
J Formos Med Assoc; 1991 Jul; 90(7):631-6. PubMed ID: 1681012
[TBL] [Abstract][Full Text] [Related]
26. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
[TBL] [Abstract][Full Text] [Related]
29. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
Barrenetxea G; Schneider J; Llorente MF
Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
[No Abstract] [Full Text] [Related]
30. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
[TBL] [Abstract][Full Text] [Related]
31. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer.
Sonoo H; Kurebayashi J
Surg Today; 1996; 26(4):250-7. PubMed ID: 8727945
[TBL] [Abstract][Full Text] [Related]
32. [The tumor markers TPA and CEA in the after care of breast cancer].
Beaufort F; Fueger GF; Steiner H
Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
[TBL] [Abstract][Full Text] [Related]
33. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
34. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
[TBL] [Abstract][Full Text] [Related]
35. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
Barillari P; Bolognese A; Chirletti P; Cardi M; Sammartino P; Stipa V
Dis Colon Rectum; 1992 May; 35(5):471-6. PubMed ID: 1568399
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S
Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053
[TBL] [Abstract][Full Text] [Related]
38. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
40. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease].
Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T
Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
